Ph.D. in Life Sciences or Molecular Biology. B.E./B.Tech./M.Sc./M.Tech. degree in any branch of Life Sciences or Chemical Sciences from a recognized university. THSTI

The candidate must have a Post Graduate degree in any branch of Life sciences. The candidate should have qualified CSIR-UGC NET, DBT-BET, GATE etc. BRIC-RGCB, Thiruvananthapuram

Post-Graduate degree in Life Sciences from a recognized university with at least one (1) year of post-qualification experience in microbiology. THSTI Interview

Exposure to OSD Manufacturing operations like Granulation, Pellet coating, Capsule filling, Primary Packing & Secondary Packing. QMS.

Production, QA and other departments; good communication and documentation skills; ability to work in a team and meet timelines; knowledge of MS Office and basic computer skills.

Experience in protocol/report preparation, protocol/report review, Analytical Data review (AMV), QMS investigations, and regulatory guideline compliance

Encube Ethicals Pvt. Ltd. We Define Excellence in Topical Formulations an Integrated Organization Dedicated to only Semisolid Formulations.

Opportunity to lead and contribute to continuous improvement initiatives that enhance product quality, operational efficiency, and compliance performance. Professional development within a global quality culture focused on quality excellence, customer satisfaction, and regulatory compliance.

Graduation in Pharmacy or Biotechnology, with hands-on experience in Autoclave, Formulation, and Washing Area). candidate shoud have regulatory plant experiance USFDA and EMA.

Review and approve the results of Engineering, Manufacturing, Quality, Service and/or Supplier evaluations and investigations of complaints.

To involve in execution of operation and cleaning of Sifting, Blending, Bin Docking, Compaction, Granulation & Dispensing and other general activities in Compounding.

Standard Operating Procedures (SOPs), cGMP requirements, and safety standards, ensuring consistent production of high-quality pharmaceutical products while meeting productivity, compliance, and quality objectives.

A team from Flinders University’s Biomedical Nanoengineering Laboratory has found that vanillin has pronounced antioxidant, anti-inflammatory and antibacterial properties, making it a good candidate for wound-healing formulations.

AstraZeneca has completed its 2 billion USD equity investment in Summit Therapeutics, strengthening a strategic partnership focused on advancing ivonescimab, a potential first-in-class bispecific antibody targeting PD-1 and VEGF, in combination with antibody-drug conjugates (ADCs) across multiple cancer types.

Zydus Lifesciences Limited, in partnership with MSN Laboratories Private Limited, has launched Riociguat Tablets in the United States, becoming the first companies to market a generic version of Bayer’s Adempas® (riociguat) in the country.

The Drugs Consultative Committee (DCC) has proposed a prominent statutory warning on cough syrup labels restricting their use in children below four years of age, amid concerns over the widespread prescribing of cough syrups to young children.

A major prospective clinical trial has identified clinical and molecular characteristics that may help determine which patients with early-stage HER2-positive breast cancer are most likely to achieve a pathologic complete response (pCR) after a shorter, less intensive chemotherapy regimen.

A cancer drug currently being evaluated in clinical trials may work through a different biological mechanism than scientists originally believed, according to a new study led by the University of Sydney in collaboration with Goethe University, the University of Oxford and the Institute of Cancer Research, London.